Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 AUD | -1.69% | -2.78% | -9.09% |
Mar. 19 | Cyclopharm's Technegas Device Carries Out Imaging of First US Patients | MT |
Mar. 18 | Cyclopharm Limited(ASX:CYC) added to S&P/ASX All Ordinaries Index | CI |
Sales 2024 * | 37.4M 24.36M | Sales 2025 * | 60.9M 39.67M | Capitalization | 168M 109M |
---|---|---|---|---|---|
Net income 2024 * | -2M -1.3M | Net income 2025 * | 11M 7.17M | EV / Sales 2024 * | 4.48 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 2.75 x |
P/E ratio 2024 * |
-70
x | P/E ratio 2025 * |
14.3
x | Employees | 87 |
Yield 2024 * |
0.57% | Yield 2025 * |
3.49% | Free-Float | 45.15% |
1 day | -1.69% | ||
1 week | -2.78% | ||
Current month | -2.51% | ||
1 month | -3.58% | ||
3 months | -5.41% | ||
6 months | -15.87% | ||
Current year | -9.09% |
Managers | Title | Age | Since |
---|---|---|---|
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
Mathew Farag
COO | Chief Operating Officer | - | 16-12-31 |
Mark Doverty
PRN | Corporate Officer/Principal | - | 19-09-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dianne Angus
BRD | Director/Board Member | 63 | 21-08-09 |
James McBrayer
CEO | Chief Executive Officer | 58 | 08-06-02 |
David Heaney
CHM | Chairman | 79 | 06-11-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 1.75 | -1.69% | 18 513 |
24-04-22 | 1.78 | 0.00% | 12,000 |
24-04-19 | 1.78 | 0.00% | 14,941 |
24-04-18 | 1.78 | -1.11% | 15,980 |
24-04-17 | 1.8 | +0.84% | 2,000 |
Delayed Quote Australian S.E., April 24, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-9.09% | 109M | |
+8.35% | 219B | |
+9.41% | 187B | |
+11.75% | 134B | |
+19.34% | 101B | |
-0.84% | 62.27B | |
+15.08% | 52.82B | |
-2.10% | 47.49B | |
+0.10% | 40.79B | |
+11.50% | 39.35B |
- Stock Market
- Equities
- CYC Stock